Risperidone plasma levels, clinical response and side-effects

European Archives of Psychiatry and Clinical Neuroscience

Volumn 255, Issue 4, 2005, Pages 261-268

  Riedel, Michael ^a   Schwarz, M J ^a   Strassnig, M ^b   Spellmann, I ^a   Muller Arends A ^a   Weber, K ^a   Zach, J ^a   Muller N ^a   Moller H J ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

9 Hydroxy risperidone; CYP2D6; HPLC; Risperidone; Schizophrenia; TDM; Therapeutic drug monitoring

Indexed keywords

CYTOCHROME P450 2D6; RISPERIDONE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; EXTRAPYRAMIDAL SYNDROME; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MONOTHERAPY; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RATING SCALE; SAMPLE SIZE; SCHIZOPHRENIA; STEADY STATE;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PYRIMIDINES; RISPERIDONE; SCHIZOPHRENIA;

EID: 23944456461     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00406-004-0556-4     Document Type: Article

References (56)

1. Alvan G, Bechtel P, Iselius L, Gundert-Remy U (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39(6):533-537
2. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, D.C., American Psychiatric Association
3. Aravagiri M, Marder SR (2002) Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. Psychopharmacol 159:424-431
4. Aravagiri M, Marder SR, Nuechterlein KH, Gitlin M (2003) Intra-and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Ther Drug Monitoring 25(6):657-664
5. Balant-Gorgia AE, Balant LP (1995) Therapeutic drug monitoring in psychiatry: relevance during the drug treatment of psychiatric disorders. CNS Drugs 4:432-453
6. Balant-Gorgia AE, Gex-Fabry M, Genet C, Balant LP (1999) Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors. Ther Drug Monitoring 21(1):105-115
7. Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, Cohen BM (1993) Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacol 9:117-124
8. Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676
9. Berecz R, LLerena A, de la Ruvia A, Gomez A, Kellermann M, Dorado P, Degrell I (2002) Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients. Pharmacopsychiatry 35:231-234
10. Boulton DW, DeVane CL, Liston HL, Markowitz JS (2002) In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Live Sci 71(2):163-169
11. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA (1991) Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 10(8):545-558
12. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM (1999) Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacocinet C37:177-193
13. Carman J, Peuskens J, Vangeneugden A (1995) Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 10:207-213
14. Carpenter WT Jr, Conley RR, Buchanan RW, Breier A, Tamminga CA (1995) Patient response and resource management: Another view of clozapine treatment of schizophrenia. Am J Psychiatry 152:827-832
15. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F (1995) Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. Pharmacol Exp Ther 274(1):516-520
16. Darby JK, Pasta DJ, Elfand L, Dabiri L, Lincoln C, John H (1997) Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J Clin Psychopharm 17(6):478-488
17. de Leon J, Bork J (1997) Risperidone and cytochrome P450 3AJ Clin Psychiatry 58:450
18. Ereshevsky L (1995) Treatment strategies for schizophrenia. Psychiatr Ann 25:285-296
19. Fang J, Borurin M, Baker GB (1999) Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Arch Pharmacol 359:147-151
20. Fenton WS, Blyler CR, Heinssen RK (1997) Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schiz Bull 23:637-651
21. Grant S, Fitton A (1994) Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 48:253-273
22. Guy W, Bunate RR (1970) Clinical global impression. In: Guy W, Bonate RR (eds) Manual for the ECDEU Assessment Battery. Chevy Chase, MD: National Institute of Mental Health 12-1-12-6
23. He H, Richardson JS (1995) A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int Clin Psychopharmacol 10:19-30
24. Heykants J, Huang ML, Mannens G, etal. (1994) The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 55(Suppl):13-17
25. Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E, Van Beijsterveldt L, Van Peer A, Woestenborghs R (1994) The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 55(Suppl):13-17
26. Kane JM, Marder SR (1993) Psychopharmacologic treatment of schizophrenia. Schiz Bull 19:287-302
27. Keepers GA, Casey DE (1991) Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects. Am J Psychiatry 148(1):85-89
28. Kronig MH, Munne RA, Szymanski S, Safferman AZ, Pollack S, Cooper T, Kane JM, Lieberman JA (1995) Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 152:179-182
29. Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151(6):825-835
30. Meltzer HY (1992) Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schiz Bull 18(3):515-542
31. Möller HJ (1999) Atypical neuroleptics: a new approach in the treatment of negative symptoms. Eur Arch Psychiatry Clin Neurosci 249(Suppl 4):IV/99-IV/107
32. Möller HJ (2003) Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs 17(11):793-823
33. Nasrallah HA, Mulvihill T (2001) Iatrogenic disorders associated with conventional vs atypical antipsychotics. Ann Clin Psychiatry 13:215-227
34. Odou P, Levron JC, Luyckx M, et al. (2000) Risperidone drug monitoring. A useful clinical tool? Clin Drug Invest 19:283-292
35. Olesen OV, Licht RW, Thomsen E, Bruun T, Viftrup JE, Linnet K (1998) Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monitoring 20(4):380-384
36. Perry PJ, Miller DD, Arndt SV, Cadoret R (1991) Clozapine and norclozapine plasma concentrations and clinical response in treatment-refractory schizophrenics. Am J Psychiatry 148:231-235
37. Perry PJ, Sanger T, Beasley C (1997) Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J Clin Psychopharm 17(6):472-477
38. Prior TI, Baker GB (2003) Interaction between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 28(2):99-112
39. Prior TI, Baker GB (2003) Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatr Neurosci 28:99-112
40. Roh H-K, Kim C-E, Chung W-G, Park C-S, Svensson J-O, Bertilsson L (2001) Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol 57(9):671-675
41. Ross-Chouinard A, Annable L, et al. (1980) The Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 7:233
42. Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60(2):284-295
43. Scordo MG, Spina E, Facciola G, et al. (1999) Cytochrome P 450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacol 147:300-305
44. Scordo MG, Spina E, Facciola G, Avenoso A, Johannsson I, Dahl M-L (1999) Cytochcorome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology 147:300-305
45. Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand (Suppl 212):11-19
46. Snoeck E, Van Peer A, Sack M, et al. (1995) Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology 122:223-229
47. Spina E, Avenoso A, Facciola G, Salemi M, Scordo MG, Ancione M, Madila AG, Perucca E (2001) Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology 153:238-243
48. Spina E, Avenoso A, Facciola G, Scordo MG, Ancione M, Madia AG, Ventimiglia A, Perucca E (2001) Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology 148:83-89
49. Stahl SM (1999) Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret? J Clin Psychiatry 60(7):425-426
50. Stahl SM (1999) Antipsychotic polypharmacy, Part 2: Tips on use and misuse. J Clin Psychiatry 60(8):506-507
51. Sumiyoshi T, Kido H, Sakamoto H, et al. (1994) In vivo dopamine-D2 and serotonin-5HT-2 receptor binding study of risperidone and Haloperidol. Pharmacol Biochem Behav 47:553-557
52. Van Beijsterveldt LEC, Geerts RJF, Leysen JE, et al. (1998) Regional brain distribution of risperidone and its active metabolite 9-hydroxyrisperidone in the brain and other tissues of rat. Psychopharmacol 139:356-363
53. Yasui-Furukori N, Mihara K, Kondo T, Kubota T, Iga T, Takarada Y, De Vries R, Kaneko S, Tateishi T (2003) Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia. J Clin Pharmacol 43(2):122-127
54. Yoshimura R, Ueda N, Nakamura J (2001) Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study. Neuropsychobiology 44(3):129-133
55. Zackrisson AL, Lindblom B (2003) Identification of CYP2D6 alleles by single nucleotide polymorphism analysis using pyrose-quencing. Eur J Clin Pharmacol 59(7):521-526. Epub 2003 Sep 06
56. Zubenko GS, Sunderland T (2000) Geriatric psychopharmacology: why does age matter? Har Rev Psychiatry 7(6):311-333